Differential effects of three preparations of human serum on expansion of various types of human cells.
Kurita M., Aiba-Kojima E., Shigeura T., Matsumoto D., Suga H., Inoue K.
Prospective Study, published in Plast Reconstr Surg (2008) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Plast Reconstr Surg (2008)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 18626359
- DOI
- 10.1097/PRS.0b013e31817d618d
Abstract (original English)
To avoid potential risks of animal-derived products such as viral transmission and immunologic reactions, usefulness of human-derived products in manipulation of cells for cell-based therapies has been investigated but has not yet been completely clarified. Three types of human sera-serum from whole blood, serum from platelet-rich plasma, and serum from platelet-poor plasma-were prepared from blood samples obtained from the same four volunteers. The authors investigated the biochemical profiles of the three serum preparations as well as their potential as culture additives using three types of human cells: dermal fibroblasts, adipose-derived stem/stromal cells, and umbilical vein endothelial cells. Platelet counts differed among serum from whole blood (100 percent), platelet-rich plasma (75.1 percent), and platelet-poor plasma (12.6 percent), resulting in differential concentrations of platelet-derived growth factor and epidermal growth factor, although other biochemical values such as total protein and albumin were similar. Serum from whole blood and platelet-rich plasma highly enhanced proliferation of dermal fibroblasts compared with the effects of serum from platelet-poor plasma, but no differences in proliferative efficacy were observed in cultures of adipose-derived stem/stromal cells and vascular endothelial cells. Serum from platelet-rich plasma, which is less invasive
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.